Evidence Library

Filter by drug, type, year, and open access.

Drug

Type

Year ≥

Sort

Open access

Active filters:Type: GUIDELINE ×Clear filters

Showing 1–50 of 112 results

Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2025)• Drug: gabapentin-enacarbilDOI
Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2025)• Drug: pramipexoleDOI
Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2025)• Drug: ropiniroleDOI
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: citalopramDOI PMID
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: amoxapineDOI PMID
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: isocarboxazidDOI PMID
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: nefazodoneDOI PMID
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: olanzapine-fluoxetineDOI PMID
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: selegilineDOI PMID
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults — Canadian Journal of Psychiatry (2024)• Drug: trimipramineDOI PMID
2023 American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults — Journal of the American Geriatrics Society (2023)• Drug: diphenhydramineDOI PMID
2023 American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults — Journal of the American Geriatrics Society (2023)• Drug: promethazineDOI PMID
APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: amoxapineOpen access
APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: isocarboxazidOpen access
Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology — Journal of Psychopharmacology (2023)• Drug: lorazepamDOI
APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: nefazodoneOpen access
APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: olanzapine-fluoxetineOpen access
APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: selegilineOpen access
APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: selegiline-transdermalOpen access
APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: tranylcypromineOpen access
APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)• Drug: trimipramineOpen access
Consensus recommendations for MAOI safety and dietary management — Journal of Clinical Psychopharmacology (2022)• Drug: isocarboxazidDOI
Consensus recommendations for MAOI safety and dietary management — Journal of Clinical Psychopharmacology (2022)• Drug: selegilineDOI
Consensus recommendations for MAOI safety and dietary management — Journal of Clinical Psychopharmacology (2022)• Drug: selegiline-transdermalDOI
The Management of Restless Legs Syndrome: An Updated Algorithm — Mayo Clinic Proceedings (2021)• Drug: gabapentin-enacarbilDOI
The Management of Restless Legs Syndrome: An Updated Algorithm — Mayo Clinic Proceedings (2021)• Drug: pramipexoleDOI
The Management of Restless Legs Syndrome: An Updated Algorithm — Mayo Clinic Proceedings (2021)• Drug: ropiniroleDOI
Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2021)• Drug: calcium-magnesium-potassium-and-sodium-oxybatesDOI
Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2021)• Drug: sodium-oxybate-extended-releaseDOI
TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: buprenorphineOpen access
TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: buprenorphine-naloxoneOpen access
TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: methadoneOpen access
TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: naltrexoneOpen access
TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: naltrexone-extended-releaseOpen access
TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: naloxoneOpen access
Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement — JAMA (2021)• Drug: nicotineDOI PMID
Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement — JAMA (2021)• Drug: vareniclineDOI PMID
The CANMAT and ISBD Guidelines for the Management of Patients With Bipolar Disorder: 2021 Update — Bipolar Disorders (2021)• Drug: olanzapine-fluoxetineDOI
CANMAT/ISBD guidance on valproate for bipolar disorder — Bipolar Disorders (2021)• Drug: valproate-divalproexDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: clonazepamDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: alprazolamDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: diazepamDOI
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management — Journal of Addiction Medicine (2020)• Drug: clorazepateDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: clorazepateDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: estazolamDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: flurazepamDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: quazepamDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: temazepamDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: triazolamDOI
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management — Journal of Addiction Medicine (2020)• Drug: oxazepamDOI